New mRNA flu shot enters human testing
NCT ID NCT05755620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single dose of a new mRNA flu vaccine (VRC H1ssF-3928) in 50 healthy adults aged 18 to 49. The vaccine aims to teach the body to fight a stable part of the flu virus. Researchers are checking for side effects and measuring immune responses, comparing them to a standard flu shot.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA flu vaccine (VRC H1ssF-3928)
What this could lead to
If successful, this could pave the way for a more effective flu vaccine that targets a stable part of the virus, potentially offering broader protection.
What could go wrong
This is a very early Phase 1 trial with only 50 people, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27704, United States